When does Acurx report earnings and how does that affect ACXP stock?

Acurx will host its earnings call on 13 Mar 2026 at 08:00 AM ET. The call will detail 2025 results and trial plans, and it is the main near-term catalyst likely to move ACXP stock due to funding and trial-timing disclosures.

What is the primary clinical catalyst for ACXP stock?

The primary catalyst is advancing ibezapolstat to Phase 3 and a new rCDI open-label pilot. Positive Phase 3 design feedback and trial starts are the fundamental drivers for ACXP stock upside.

What is Meyka AI's price forecast for ACXP stock?

Meyka AI's forecast model projects a 12‑month price of **$3.95**, implying **36.21%** upside from **$2.90** today. Forecasts are model-based projections and not guarantees.

What are the biggest risks that could hurt ACXP stock?

Key risks include failure to secure funding for Phase 3, trial delays or negative results, and regulatory setbacks. ACXP stock is volatile and highly dependent on clinical and regulatory outcomes.

US Stocks

ACXP Acurx Pharmaceuticals NASDAQ 10 Mar 2026: Ibezapolstat trial headlines earnings

ByDanny Kontos March 11, 2026March 11, 2026

ACXP stock climbed 48.34% to $2.90 on 10 Mar 2026 after Acurx Pharmaceuticals announced a new ibezapolstat trial and confirmed an earnings call for 13 Mar 2026. The move came on 31,258,669 shares traded, vastly above the 50-day average of 157,135 shares. We examine what the trial update means for the upcoming ACXP earnings, valuation, and the path to Phase 3 and potential approvals.